



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: JAN K. CAERS, et al.)	Examiner:
)	
Serial Number: 10/621,054)	Art Unit: 1645
)	
Filed: July 15, 2003)	Confirmation No. 8812
)	
For: DEVICE TO ASSIST)	
<u>HYPERHYDROSIS THERAPY</u>)	Irvine, California

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant's provide with regard to the patent application entitled DEVICE TO ASSIST HYPERHYDROSIS THERAPY, filed herewith one copy of a documents of which they are aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of documents submitted is set forth on the attached Information Disclosure Citation (Form PTO-1449).


While these documents may be material pursuant to 37 C.F.R. §1.56, their disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.



Respectfully submitted,

Date: December 11, 2003


Stephen Donovan
Registration Number 33,433

Please direct all inquiries and correspondence to:

Stephen Donovan
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534


CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed herein are being deposited with the United States Postal Service on this date December 11, 2003, in an envelope as "Express Mail Post Office to Addressee" Mailing Label number EV193721385US addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Date: December 11, 2003

Susan Bartholomew

Name of person mailing paper


Signature of person mailing paper

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17595 (BOT)	SERIAL NO.: 10/621,054
APPLICANT CAERS, J. et al.	TITLE: DEVICE TO ASSIST HYPERHYDROSIS THERAPY
FILING DATE: July 15, 2003	GROUP 1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	5,437,291	8-1-1995	Pasricha et al.			
	AB	5,670,484	9-23-1997	Binder			
	AC	5,714,468	2-3-1998	Binder			
	AD	5,766,605	6-16-1998	Sanders et al.			
	AE	6,063,768	5-16-2000	First			
	AF	6,113,915	9-5-2000	Aoki et al.			
	AG	6,139,845	10-31-2000	Donovan			
	AH	6,143,306	11-7-2000	Donovan			
	AI	6,265,379 B1	7-24-2001	Donovan			
	AJ	6,299,893 B1	10-9-2001	Schwartz et al.			
	AK	6,306,403 B1	10-23-2001	Donovan			
	AL	6,306,423 B1	10-23-2001	Donovan et al.			
	AM	6,312,708 B1	11-6-2001	Donovan			
	AN	6,328,977 B1	12-11-2001	Donovan			
	AO	6,358,513 B1	3-19-2002	Voet et al.			
	AP	6,365,164 B1	4-2-2002	Schmidt			
	AQ	6,395,277 B1	5-28-2002	Graham			
	AR	6,423,319 B1	7-23-2002	Brooks et al.			
	AS	6,458,365 B1	10-1-2002	Aoki et al.			
	AT	6,464,986 B1	10-15-2002	Aoki et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/n)
	BA						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)


CA	Bigalke, Hans et al., <i>Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture</i> ; <i>Brain Res</i> ; 1985; 360: pp 381-24
CB	Bigalke, H. et al., <i>Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations from Rat Brain and Spinal Cord</i> ; <i>Naunyn Schmiedeberg's Arch Pharmacol</i> ; 1981; 316; pp 244-51

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17595 (BOT)	SERIAL NO.:	10/621,054
APPLICANT	CAERS, J. et al.	TITLE:	DEVICE TO ASSIST HYPERHYDROSIS THERAPY
FILING DATE:	July 15, 2003	GROUP	1645



CC	Binz, Thomas et al., <i>The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins</i> ; <u>J Biochem</u> ; (Tokyo) 1990 Jun 5; 265(16); pp 9153-8
CD	Boyd, R.S. et al., <i>The insulin secreting B-cell line, HIT-15, contains SNAP-25 which is a target for botulinum neurotoxin-A</i> ; <u>Mov. Disorders</u> ; 1995; May; 10(3); 376
CE	Bushara, K.; <i>Botulinum toxin and rhinorrhea</i> ; <u>Otolaryngol Head Neck Surg</u> , 1996; 114(3); 507
CF	Ferrari, David M. et al., <i>The protein disulphide-isomerase family: unravelling a string of folds</i> ; <u>Biochem J</u> ; 1999 (339) pp 1-10
CG	Grimalt, R. et al.; <i>Multi-injection plate for Botulinum toxin application in the treatment of axillary hyperhidrosis</i> ; <u>Dermatol Surg</u> ; 2001, Jun;27(6); 543-544
CH	Habermann, E.; <i>I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord</i> ; <u>Nauny-Schmiedeberg's Arch Pharmacol</u> ; 1974; 281; 47-56
CI	Habermann, E., <i>Inhibition by tetanus and botulinum A toxin of the release of {3H}noradrenaline and {3H}GABA from rat brain homogenate</i> ; <u>Experientia</u> ; 1988, Mar 15; 44(3) pp 224-6
CJ	Habermann, E. et al., <i>Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release from Cultured Mouse Brain</i> ; <u>J Neurochem</u> ; Vol 51, No 2 1988; pp 522-7
CK	Jankovic, Joseph et al., <i>Therapy with Botulinum Toxin</i> ; Marcel Dekker, Inc.; pp 5
CL	Marjama-Lyons, Jill et al., <i>Tremor-Predominant Parkinson's Disease</i> ; <u>Drugs & Aging</u> ; 2000; April 16 (4) pp273-278
CM	Moyer, E. et al.; <i>Botulinum Toxin Type B: Experimental and Clinical Experience</i> , pp 71-85 (chapter 6) of <u>Therapy With Botulinum Toxin</u> , edited by Jankovic, J. et al.; Marcel Dekker, Inc. 1994
CN	Naumann, Markus et al., <i>Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions</i> ; <u>European Journal of Neurology</u> ; 1999, Vol 6 (suppl 4) pp S111-5
CO	Naumann, M.; <i>Botulinum toxin type A in the treatment of focal hyperhidrosis</i> ; <u>J. Cutaneous Laser Therapy</u> , 2001;3(1); 42-43
CP	Pearce, Bruce et al., <i>Pharmacologic Characterization of Botulinum toxin for Basic Science and Medicine</i> ; <u>Toxicon</u> ; 1997; 35 (9); pp 1373-412 at 1393
CQ	Sanchez-Prieto, Jose et al., <i>Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes</i> ; <u>Eur J Biochem</u> ; 1987 Jun; 165 (3); pp 675-81

EXAMINER _____

DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17595 (BOT)	SERIAL NO.:	10/621,054
APPLICANT	CAERS, J. et al.	TITLE:	DEVICE TO ASSIST HYPERHYDROSIS THERAPY
FILING DATE:	July 15, 2003	GROUP	1645

CR	Schantz, Edward J. et al., <i>Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine</i> ; <u>Microbiol Review</u> ; 1992 Mar; 56 (1); pp 80-99
CS	Singh; <i>Critical Aspects of Bacterial Protein Toxins</i> ; pp63-84 (chapter 4) of <u>Natural Toxins II</u> , edited by B.R. Singh et al., Plenum Press, New York 1976
CT	Sloop, Richard R. et al., <i>Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use</i> ; <u>Neurology</u> ; 1997, Jan; 48 (1); pp 249-53
CU	Weigand et al.; <i>I-Labelled Botulinum A Neurotoxin: Pharmacokinetics in Cats after Intramuscular Injection</i> ; <u>Naunyn-Schmiedeberg's Arch Pharmacol</u> ; 1976, 292; 161-165

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.